×
About 2,559 results

ALLMedicine™ Cardiovascular Risk Management Center

Research & Reviews  281 results

Can cardiovascular risk management be improved by shared care with general practice to ...
https://doi.org/10.1186/s12877-020-01760-z
BMC Geriatrics; Davison WJ, Myint PK et. al.

Sep 18th, 2020 - Cognitive impairment and dementia following cerebrovascular disease are increasingly common in the UK. One potential strategy to prevent post-stroke cognitive decline is multimodal vascular risk factor management. However, its efficacy remains unc...

Effectiveness of a prevention program in the incidence of cardiovascular outcomes in a ...
https://doi.org/10.1186/s12889-020-09516-5
BMC Public Health; Miranda-Machado P, Salcedo-Mejía F et. al.

Sep 18th, 2020 - Cardiovascular diseases (CVDs) and diabetes mellitus (DM) are among the leading cause of morbidity and mortality in low-and-middle-income countries (LMICs) but evidence in these contexts regarding the effectiveness of primary prevention interventi...

Long-term Prognosis After Elective Abdominal Aortic Aneurysm Repair is Poor in Women an...
https://doi.org/10.1097/SLA.0000000000004182
Annals of Surgery; Bulder RMA, Talvitie M et. al.

Jul 13th, 2020 - To evaluate the impact of changes in elective Abdominal Aortic Aneurysm (AAA) management on life-expectancy of AAA patients. Over the past decades AAA repair underwent substantial changes, that is, the introduction of EVAR and implementation of in...

Obesity and cardiovascular risk management is a critical way to reduce healthcare resou...
https://doi.org/10.1177/2047487320929248
European Journal of Preventive Cardiology; Chen L, Hao G

Jun 1st, 2020 - Obesity and cardiovascular risk management is a critical way to reduce healthcare resource pressure.|2020|Chen L,Hao G,|

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.
https://doi.org/10.2337/dc20-0941
Diabetes Care; Ceriello A, Standl E et. al.

May 15th, 2020 - People with diabetes compared with people without exhibit worse prognosis if affected by coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly when compromising metabolic cont...

see more →

Guidelines  5 results

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduct...
http://www.onlinejacc.org/content/early/2018/11/23/j.jacc.2018.09.020

Nov 25th, 2018 - Despite major therapeutic advances leading to improved outcomes over the past 2 decades, cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D) (1). Over that time, the prevalence of.

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of ...
http://www.onlinejacc.org/content/early/2018/11/02/j.jacc.2018.11.003
Grundy, S.,et al

Nov 9th, 2018 - The recommendations listed in the present guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLIN.

Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
http://care.diabetesjournals.org/lookup/doi/10.2337/dc18-S009
American Diabetes Association

Dec 31st, 2017 - Atherosclerotic cardiovascular disease (ASCVD)—defined as coronary heart disease, cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin—is the leading cause of morbidity and mortality for individuals with.

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Sta...
http://www.onlinejacc.org/content/early/2017/08/30/j.jacc.2017.07.745
Lloyd-Jones, D.,et al.

Sep 4th, 2017 - In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density lipoprotein (LDL)–cholesterol lowering in the management of atherosclerotic cardiovascular.

EULAR evidence-based recommendations for cardiovascular risk management in patients wit...
https://doi.org/10.1136/ard.2009.113696
Annals of the Rheumatic Diseases; Peters MJ, Symmons DP et. al.

Sep 23rd, 2009 - To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). A multidisciplinary expert committee was convened as a t...

see more →

Drugs  983 results see all →

Clinicaltrials.gov  1,279 results

Can cardiovascular risk management be improved by shared care with general practice to ...
https://doi.org/10.1186/s12877-020-01760-z
BMC Geriatrics; Davison WJ, Myint PK et. al.

Sep 18th, 2020 - Cognitive impairment and dementia following cerebrovascular disease are increasingly common in the UK. One potential strategy to prevent post-stroke cognitive decline is multimodal vascular risk factor management. However, its efficacy remains unc...

Effectiveness of a prevention program in the incidence of cardiovascular outcomes in a ...
https://doi.org/10.1186/s12889-020-09516-5
BMC Public Health; Miranda-Machado P, Salcedo-Mejía F et. al.

Sep 18th, 2020 - Cardiovascular diseases (CVDs) and diabetes mellitus (DM) are among the leading cause of morbidity and mortality in low-and-middle-income countries (LMICs) but evidence in these contexts regarding the effectiveness of primary prevention interventi...

Verapamil hydrochloride - verapamil hydrochloride tablet, film coated, extended release-American Health Packaging
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=346e7bfe-ae8a-4128-a127-6fb5123bb6b9

Sep 16th, 2020 - Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infar...

Calan sr - verapamil hydrochloride tablet, film coated, extended release-G.D. Searle LLC Division of Pfizer Inc
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acb6e57b-af44-432f-a4de-a293a2e20121

Sep 16th, 2020 - CALAN SR is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in ...

Lisinopril and hydrochlorothiazide - lisinopril and hydrochlorothiazide tablets tablet-NuCare Pharmaceuticals,Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af74c331-7402-408c-e053-2a95a90a1043

Sep 15th, 2020 - Lisinopril and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarc...

see more →

News  11 results

Cardiovascular risk management supported for type 2 diabetes
https://www.mdedge.com/neurology/article/172877/mixed-topics/cardiovascular-risk-management-supported-type-2-diabetes

Aug 17th, 2018 - Two studies published in the New England Journal of Medicine support managing cardiovascular risk in patients with type 2 diabetes. Also today, spontaneous intracranial hypotension is a triple misnomer, prolonged antimalarial therapy is linked to.

Studies support cardiovascular risk management in T2DM
https://www.mdedge.com/familymedicine/article/172698/diabetes/studies-support-cardiovascular-risk-management-t2dm/page/0/1
Clinical Endocrinology News;

Aug 15th, 2018 - The second study, which included 271,174 patients with T2DM from the Swedish National Diabetes Register and 1,355,870 controls, examined five risk factors: elevated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, alb.

LDL particle number advantageous in managing cardiovascular risk
https://www.mdedge.com/internalmedicine/article/81826/cad-atherosclerosis/ldl-particle-number-advantageous-managing
Bruce Jancin

Apr 23rd, 2014 - WASHINGTON – High-risk patients managed to a target LDL particle number rather than to an LDL cholesterol goal had 25% fewer cardiovascular events over 3 years of follow-up. "These new data add to the growing body of evidence suggesting that [nucl.

Arthritis Plus Hypothyroidism Ups Women's CVD Risk
https://www.mdedge.com/rheumatology/article/48975/cad-atherosclerosis/arthritis-plus-hypothyroidism-ups-womens-cvd-risk
Denise Napoli

Mar 19th, 2012 - Women with both hypothyroidism and inflammatory arthritis have a nearly fourfold greater risk of developing heart disease, compared with controls. The finding adds to "sparse" data on the long-hypothesized association between hypothyroidism and in.

CRP, Other CV Biomarkers Add Little to Clinical Management
https://www.medpagetoday.com/cardiology/atherosclerosis/14920

Jun 30th, 2009 - Action Points Explain to interested patients that biomarkers are laboratory-assessed compounds in the blood linked to outcomes of interest, such as risk of a future heart attack. Note that the studies did not refute the role of inflammation in hea...

see more →